Lorcaserin Weight-Loss Pill Is The “Holy Grail” In Combating Obesity, And Is Safe For Heart Health

A weight-loss pill is the new “holy grail” against obesity as it the scientists deemed it safe for heart health after a major study has been conducted across the US. We’re talking about Lorcaserin, new “magical” substance that fights against overweight, which is an appetite suppressant by stimulating the brain to induce the feeling of satiety faster.

In the recent US study on this new drug, 12,000 overweight and obese Americans participated. The subjects were divided into two groups, one taking the weight-loss pill, while the other being given a placebo. By the end of the study, those who took Lorcaserin for twice a day lost 4 kilos, while the placebo group only 1,5 kg.

More importantly, however, the researchers found that this substance had no side effects on the heart health, deeming the chemical compound safe for long-term consumption. Thus, the new “holy grail” of slimming pills might indeed be helpful in combating obesity without adverse effects on the circulatory system.

A Lorcaserin-based weight-loss pill can fight against obesity without damaging the heart health

The Food and Drug Administration in the US, the renowned FDA, has already approved Lorcaserin across the US since 2012. The substance is found in pharmacies under the name Belviq since 2013. However, the new study, led by Dr. Erin Bohula, a cardiovascular medicine expert at the Harvard-affiliated Brigham and Women’s Hospital, was the first one to assess the long-term effect of Lorcaserin.

“Patients and their doctors have been nervous about using drugs to treat obesity and for a good reason. There’s a history of these drugs having serious complications,” said Dr. Erin Bohula.

According to the study, over one year, 39% of the subjects given Lorcaserin weight-loss pill shed 5% of their starting weight, while only 17% of the control group achieved similar results.

“The higher weight-loss rates were achieved without an accompanying increase in the risk of cardiovascular events,” concluded Dr. Bohula.